  |
 | Up a level |
Rugo, H.S. and Pennella, E.J. and Gopalakrishnan, U. and Hernandez-Bronchud, M. and Herson, J. and Koch, H.F. and Loganathan, S. and Deodhar, S. and Marwah, A. and Manikhas, A. and Bondarenko, I. and Parra, J.D. and Abesamis-Tiambeng, M.L.T. and Akewanlop, C. and Vynnychenko, I. and Sriuranpong, V. and Roy, S. and Yanez Ruiz, E.P. and Barve, A. and Waller, C.F. (2021) Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial. The Breast, 58. pp. 18-26. ISSN 0960-9776
Ellis, M.J. and Bondarenko, I. and Trishkina, E. and Dvorkin, M. and Panasci, L. and Manikhas, A. and Shparyk, Y. and Cardona-Huerta, S. and Cheung, K-L. and Philco-Salas, M.J. and Ruiz-Borrego, M. and Shao, Z. and Noguchi, S. and Grinsted, L.M. and Fazal, M. and Stuart, M. and Robertson, J.F. (2016) FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer. Annals of Oncology, Vol.27 (supp6). P.-LBA14_PR. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
